Human Oncostatin M Recombinant
Catalog #
90227-B
$205
*
●
●
Purchase
Description
Recombinant Oncostatin-M is a disulfide-linked homodimeric protein consisting of 228 amino acid residues, and migrates as an approximately 26 kDa protein under non-reducing and reducing conditions in SDS-PAGE. Optimized DNA sequence encoding Human Oncostatin-M mature chain was expressed in E. coli.
●
Synonyms
OSM, Oncostatin-M
Product Info
Storage and Usage
Citations
Species
Human
Host Species/Expression System
E. coli
Purity
≥95% by SDS-PAGE and HPLC
Format
lyophilized protein
Formulation
Lyophilized from a 0.2 µm filtered concentrated (1 mg/ml) PBS solution, pH 7.0.
MW
26 kDa
Endotoxin Level
<0.1 ng/µg (1 EU/µg), using the LAL gel clot method.
Amino Acids
26–252
Biological Activity
The ED50 was determined by the dose-dependent stimulation of the proliferation of f human TF-1 cells is ≤ 3 ng/ml, corresponding to a specific activity of ≥ 2 x 105 units/mg.
Genbank #
P13725
UniProt #
P13725
Background
Oncostatin M is produced by monocytes and T-cells after cell activation, adherent macrophages, and various T- cell lines. Oncostatin M is a member of the IL-6-related cytokine subfamily that includes IL-6, IL-11, LIF, CNTF and CT-1. Oncostatin M mediates its bioactivities through two different heterodimer receptors. They both involve gp130 as a signal transducing moiety, which is found also in receptors for a number of other cytokines. When gp130 dimerizes with LIF receptor beta subunit this generates the high affinity type 1 OSM receptor. When gp130 dimerizes with a protein known as OSM receptor beta this generates the type 2 OSM receptor. Both OSM receptors activate the receptor-associated Janus kinases JAK1, JAK2, and TYK2. Signaling also involves the transcriptional activators STAT3 and STAT5b. was specifically activated through the gp130-OSM-R-beta type II heterocomplex. The signaling pathway differences observed between the common type I LIF/OSM receptor and the specific type II OSM receptor might explain some of the bioactivities specifically displayed by OSM. Oncostatin M inhibits the growth of several tumor cell lines (A375 melanoma, lung carcinomas). The antiproliferative activity of oncostatin M for some cell lines is synergised by TGF-beta and IFN-gamma. It promotes the growth of human fibroblasts, vascular smooth muscle cells, and some normal cell lines. Oncostatin can inhibit the proliferation of murine M1 myeloid leukemic cells and induces their differentiation into macrophage-like cells, a function shared by LIF, G-CSF, and IL-6.
References
1. Am. J. Respir. Cell Mol. Biol., May 2009, 40: 620 - 630.
2. J. Virol., Apr 2009, 83: 3298 - 3311.
3. Clin. Cancer Res., Mar 2009, 15: 1519 - 1526.
2. J. Virol., Apr 2009, 83: 3298 - 3311.
3. Clin. Cancer Res., Mar 2009, 15: 1519 - 1526.
Powered by Bioz
6405 Mira Mesa Blvd. Suite 100
San Diego, CA 92121
858-202-1401
San Diego, CA 92121
858-202-1401
Products are for Research Use Only
COMPANY
Copyright © 2024
BPS Bioscience, Inc.
All rights reserved.
Diagrams on this website are created with BioRender.com.